Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (PRECYCLE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03220178
Recruitment Status : Recruiting
First Posted : July 18, 2017
Last Update Posted : March 25, 2019
Sponsor:
Collaborators:
WSG WOMEN´S HEALTHCARE STUDY GROUP
CANKADO
Pfizer
AGO-TraFo
AGO-B
Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
Information provided by (Responsible Party):
Palleos Healthcare GmbH

Tracking Information
First Submitted Date  ICMJE July 6, 2017
First Posted Date  ICMJE July 18, 2017
Last Update Posted Date March 25, 2019
Actual Study Start Date  ICMJE July 24, 2017
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 14, 2017)
DQoL [ Time Frame: From start of study treatment up to 4 years ]
The event "deterioration of quality of life" (DQoL) will be measured every 28 days after enrolment using the FACT-B scale.
Original Primary Outcome Measures  ICMJE Same as current
Change History Complete list of historical versions of study NCT03220178 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures  ICMJE
 (submitted: July 14, 2017)
  • Progression-free survival [ Time Frame: From start of study treatment up to 4 years ]
    Progression-free survival (PFS) is considered to be the main clinical outcome and is defined as the time between treatment allocation and either first documentation of objective progression of disease (PD), as assessed by Investigator or death due to any cause in absence of PD.
  • Overall survival [ Time Frame: From start of study treatment up to 4 years ]
    Overall survival (OS) is defined as the time between treatment allocation and death due to any cause.
  • Drug intake [ Time Frame: From start of study treatment up to 4 years ]
    Daily electronic documentation of dosage and time of drug intake.
  • Global health status [ Time Frame: From start of study treatment up to 4 years ]
    Daily electronic rating of overall health-related quality of life on a visual analogue scale (EQ-VAS) between 100 (best health imaginable) and 0 (worst health imaginable).
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy
Official Title  ICMJE PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of eHealth-based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated With Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant
Brief Summary In this study the investigators assess the impact of the eHealth-supported therapy management system CANKADO on Quality of Life in patients with HR+, HER2-locally advanced or metastatic breast cancer treated with the cyclin dependent kinase 4/6 (CDK4/6) Inhibitor Palbociclib in combination with an aromatase inhibitor or fulvestrant. Furthermore this approach will be combined with biomarker screening to identify predictive markers for and to learn more about adherence, symptoms, response, and resistance.
Detailed Description

This is a multicenter (80 sites) , randomized, parallel-group, Phase IV clinical trial with the primary objective of testing the hypothesis of superiority for time to deterioration (TTD) in patients using the ePRO system CANKADO active over CANKADO inform version.

Eligible patients will have histologically or cytologically proven diagnosis of hormone receptor positive (HR+), human epidermal growth factor receptor 2 (HER2)- negative locally advanced or metastatic breast cancer and will be either candidates to receive palbociclib in combination with aromatase inhibitor or candidates to receive palbociclib in combination with fulvestrant for their locally advanced or metastatic disease. Patients who are candidates for palbociclib in combination with aromatase inhibitor (AI) or fulvestrant will not be candidates for curative therapies. For Patients who are candidates for palbociclib in combination with aromatase inhibitor or fulvestrant one prior line of chemotherapy for locally advanced or metastatic breast cancer is allowed in addition to a maximum of two lines of endocrine therapy. Patients will be stratified according their eligibility of receiving palbociclib with endocrine therapy (AI or fulvestrant) as first or later lines.

Patients allocated to the combination of palbociclib with aromatase inhibitor will receive:

  • Palbociclib, 125 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment and
  • Aromatase inhibitor, orally once-daily (continuously).
  • Pre- or peri-menopausal patients should additionally receive a Gonadotropin-Releasing-Hormon (GnRH)-agonist

Patients allocated to the combination of palbociclib with fulvestrant will receive:

  • Palbociclib, 125 mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment and
  • Fulvestrant , 500 mg, intramuscularly on Days 1 and 14 of Cycle 1, every 28 days (± 7 days) thereafter starting.
  • Pre- or peri-menopausal patients should additionally receive a Gonadotropin-Releasing-Hormon (GnRH)-agonist

Patients of each treatment group (palbociclib / aromatase inhibitor and palbociclib/fulvestrant) will randomized 2:1 in the Intervention Arm A CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome (HDOB-PRO).

And in the Control Arm B CANKADO inform stands for a CANKADO-based eHealth service with a personal login. On-site surveys without feedback functions for the patient will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from at home and can document their drug intake. Further features will not be available.

Patients will continue to receive study treatment together with the assigned ePRO assessment until investigator assessed disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurs first. In addition, should palbociclib related toxicity mandate discontinuation; patients can continue to receive fulvestrant alone.

Patients discontinuing the active treatment phase will enter a follow-up period phase during survival further progression and new anti-cancer therapy information will be collected once a year up to 48 month after randomization.

In addition biomarkers will be assessed as a scientific program within this study. Tumor material (tumor tissue and Blood samples (plasma and serum)) will be collected. Tumor tissue from available primary tumor and available biopsies from recurrent disease will be collected. Blood samples will be collected at four time points (cycle 1 (C1D1), after 2 weeks (C1D14), after 12 weeks (C4D1), and upon progression (End of treatment).

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Breast Neoplasm
Intervention  ICMJE
  • Drug: Palbociclib
    Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
  • Drug: Fulvestrant
    500mg per use-after first application, again at wk2, then once per month
  • Drug: Anastrozole
    1mg per day
  • Drug: Letrozole
    2,5mg/day
  • Drug: Exemestane
    25mg/day
Study Arms  ICMJE
  • Experimental: CANKADO active
    CANKADO active is the fully functional CANKADO-based eHealth treatment support service, including a high density observation of patient reported outcome.
    Interventions:
    • Drug: Palbociclib
    • Drug: Fulvestrant
    • Drug: Anastrozole
    • Drug: Letrozole
    • Drug: Exemestane
  • CANKADO inform
    CANKADO inform stands for a CANKADO-based eHealth service with a personal login. For the patient , on-site surveys without feedback functions and a dosing tracker to document daily drug intake will be available. CANKADO inform will be used for the initial ePRO and further on-site ePROs. Patients can login from home, but they will only get text information about their disease and treatment. Further features will be unavailable.
    Interventions:
    • Drug: Palbociclib
    • Drug: Fulvestrant
    • Drug: Anastrozole
    • Drug: Letrozole
    • Drug: Exemestane
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: July 14, 2017)
960
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 31, 2025
Estimated Primary Completion Date December 31, 2024   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Post- or pre/peri-menopausal female patients, age ≥18 years
  2. Patients with metastatic or locally advanced (non-operable) breast cancer disease
  3. Patients who are appropriate candidates for aromatase inhibitor + palbociclib combination therapy OR Patients having already received endocrine therapy who are appropriate candidates for fulvestrant+ palbociclib combination therapy
  4. Patient has not received treatment for locally advanced or metastatic disease OR Patient has received one prior line of chemotherapy and/or a maximum of two endocrine therapy lines for locally advanced or metastatic disease
  5. Peri-/pre-menopausal patients should additionally receive a GnRH-agonist..
  6. The tumor must be hormone-receptor positive
  7. The tumor must be HER2-negative defined as either HER2 immunohistochemistry Score 0 or 1+ or as HER2-negative by in situ hybridization..
  8. Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  9. Adequate organ and marrow function
  10. In case of patients of child bearing potential: negative serum pregnancy test at baseline. Patients must agree to use highly effective non-hormonal contraception
  11. Resolution of all acute toxic effects of prior therapy, including radiotherapy grade <1 (except toxicities not considered a safety risk for the patient) and recovery from surgical procedures
  12. Signed Written Informed Consent
  13. Willingness and capability to use CANKADO
  14. Availability of hardware: Computer and/or tablet and/or smartphone with internet access

Exclusion Criteria:

  1. Known hypersensitivity to aromatase inhibitor, fulvestrant, palbociclib or any of its excipients
  2. Contraindication for aromatase inhibitor, fulvestrant or palbociclib; or GnRH-agonists (if pre-menopausal)
  3. Prior treatment with any inhibitor of cyclin dependent kinase (CDK).
  4. Patients with locally advanced or metastatic, symptomatic, visceral spread, who are at risk of life threatening complications in the short term
  5. Known active uncontrolled or symptomatic central nervous system metastases
  6. Current use of food or drugs known to be potent inhibitors or inducers of Cytochrome P450 3A4 (CYP3A4)
  7. High cardiovascular risk, including, but not limited to recent myocardial infarction, severe/unstable angina, or severe cardiac dysrhythmias in the past 6 months of enrollment
  8. Diagnosis of any second malignancy within the last 5 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
  9. Participation in other clinical trials involving investigational drug(s) (Phases 1-4) within 2 weeks before the current study begins and/or during study participation
  10. Lactating women
  11. Life expectancy < 3 months
  12. Known infection with HIV, hepatitis B virus, or hepatitis C virus
  13. Concurrent severe, uncontrolled systemic disease, social or psychiatric condition that might interfere with the planned treatment and with the patient's adherence to the protocol
  14. Legal incapacity or limited legal capacity.
Sex/Gender  ICMJE
Sexes Eligible for Study: Female
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Palleos Healthcare GmbH 0049611 950 190 ext 0 info@palleos.com
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03220178
Other Study ID Numbers  ICMJE PH001-PreCycle
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Palleos Healthcare GmbH
Study Sponsor  ICMJE Palleos Healthcare GmbH
Collaborators  ICMJE
  • WSG WOMEN´S HEALTHCARE STUDY GROUP
  • CANKADO
  • Pfizer
  • AGO-TraFo
  • AGO-B
  • Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V.
Investigators  ICMJE
Study Director: Iris Reiser, PhD Palleos Healthcare GmbH
PRS Account Palleos Healthcare GmbH
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP